Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
| 対象疾患 | Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 |
|---|---|
| 相 | 第1/2相 |
| スポンサー | National Cancer Institute (NCI) |
| ステータス | 実施中（募集終了） |
| 参加者数 | 22 名 |
| 介入（薬剤） | Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography, Osimertinib, Positron Emission Tomography |
| 開始日 | 2020年3月16日 |
| 完了日 | 2024年6月12日 |
| 結果公開日 | 2025年6月19日 |
概要
This phase Ib trial studies the side effects and best dose of telaglenastat hydrochloride when given together with osimertinib in treating patients with stage IV non-small cell lung cancer and a mutation in the EGFR gene. Telaglenastat hydrochloride and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Recommended Phase II Dose (RP2D)
| Phase 1b Cohorts | 800 milligrams |
|---|---|
| Phase 1b Cohorts | 80 milligrams |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer — M.D. Anderson Cancer Center
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tum — National Cancer Institute (NCI)
- Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients W — National Cancer Institute (NCI)
- A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients W — AstraZeneca
- Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therap — National Cancer Institute (NCI)
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With — National Cancer Institute (NCI)